These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents. Hekmatpanah CR; Peroutka SJ Eur J Pharmacol; 1990 Feb; 177(1-2):95-8. PubMed ID: 1971219 [TBL] [Abstract][Full Text] [Related]
23. Effects of ethanol and 3,4-methylenedioxymethamphetamine (MDMA) alone or in combination on spontaneous and evoked overflow of dopamine, serotonin and acetylcholine in striatal slices of the rat brain. Riegert C; Wedekind F; Hamida SB; Rutz S; Rothmaier AK; Jones BC; Cassel JC; Jackisch R Int J Neuropsychopharmacol; 2008 Sep; 11(6):743-63. PubMed ID: 18248690 [TBL] [Abstract][Full Text] [Related]
24. Effects of "Legal X" piperazine analogs on dopamine and serotonin release in rat brain. Baumann MH; Clark RD; Budzynski AG; Partilla JS; Blough BE; Rothman RB Ann N Y Acad Sci; 2004 Oct; 1025():189-97. PubMed ID: 15542717 [TBL] [Abstract][Full Text] [Related]
25. Tolerance to 3,4-methylenedioxymethamphetamine is associated with impaired serotonin release. Jones K; Brennan KA; Colussi-Mas J; Schenk S Addict Biol; 2010 Jul; 15(3):289-98. PubMed ID: 20477756 [TBL] [Abstract][Full Text] [Related]
26. Direct effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia nigra pars reticulata, and the dorsal raphé nucleus slices. Iravani MM; Asari D; Patel J; Wieczorek WJ; Kruk ZL Synapse; 2000 Jun; 36(4):275-85. PubMed ID: 10819905 [TBL] [Abstract][Full Text] [Related]
27. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on 5-HT cell firing and release: comparison between dorsal and median raphe 5-HT systems. Gartside SE; McQuade R; Sharp T Neuropharmacology; 1997; 36(11-12):1697-703. PubMed ID: 9517441 [TBL] [Abstract][Full Text] [Related]
28. The neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA-ergic terminals: an in-vitro autoradiographic study in rats. Armstrong BD; Noguchi KK Neurotoxicology; 2004 Dec; 25(6):905-14. PubMed ID: 15474609 [TBL] [Abstract][Full Text] [Related]
29. Role of 5-HT Esaki H; Sasaki Y; Nishitani N; Kamada H; Mukai S; Ohshima Y; Nakada S; Ni X; Deyama S; Kaneda K Eur J Pharmacol; 2023 May; 946():175653. PubMed ID: 36907260 [TBL] [Abstract][Full Text] [Related]
30. MDMA ('ecstasy') enhances basal acetylcholine release in brain slices of the rat striatum. Fischer HS; Zernig G; Schatz DS; Humpel C; Saria A Eur J Neurosci; 2000 Apr; 12(4):1385-90. PubMed ID: 10762366 [TBL] [Abstract][Full Text] [Related]
31. In vitro neuronal and vascular responses to 5-hydroxytryptamine: modulation by 4-methylthioamphetamine, 4-methylthiomethamphetamine and 3,4-methylenedioxymethamphetamine. Murphy J; Flynn JJ; Cannon DM; Guiry PJ; McCormack P; Baird AW; McBean GJ; Keenan AK Eur J Pharmacol; 2002 May; 444(1-2):61-7. PubMed ID: 12191583 [TBL] [Abstract][Full Text] [Related]
32. Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Kehne JH; Ketteler HJ; McCloskey TC; Sullivan CK; Dudley MW; Schmidt CJ Neuropsychopharmacology; 1996 Aug; 15(2):116-24. PubMed ID: 8840347 [TBL] [Abstract][Full Text] [Related]
33. The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system. White SR; Obradovic T; Imel KM; Wheaton MJ Prog Neurobiol; 1996 Aug; 49(5):455-79. PubMed ID: 8895996 [TBL] [Abstract][Full Text] [Related]
34. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Verrico CD; Miller GM; Madras BK Psychopharmacology (Berl); 2007 Jan; 189(4):489-503. PubMed ID: 16220332 [TBL] [Abstract][Full Text] [Related]
36. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners. Huether G; Zhou D; Rüther E J Neural Transm (Vienna); 1997; 104(8-9):771-94. PubMed ID: 9451711 [TBL] [Abstract][Full Text] [Related]
37. MDMA-induced c-Fos expression in oxytocin-containing neurons is blocked by pretreatment with the 5-HT-1A receptor antagonist WAY 100635. Hunt GE; McGregor IS; Cornish JL; Callaghan PD Brain Res Bull; 2011 Aug; 86(1-2):65-73. PubMed ID: 21745546 [TBL] [Abstract][Full Text] [Related]
38. Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/1D) receptors. McCreary AC; Bankson MG; Cunningham KA J Pharmacol Exp Ther; 1999 Sep; 290(3):965-73. PubMed ID: 10454466 [TBL] [Abstract][Full Text] [Related]
39. Effect of a serotonin depleting regimen of 3,4-methylenedioxymethamphetamine (MDMA) on the subsequent stimulation of acetylcholine release in the rat prefrontal cortex. Nair SG; Gudelsky GA Brain Res Bull; 2006 Apr; 69(4):382-7. PubMed ID: 16624669 [TBL] [Abstract][Full Text] [Related]
40. Neuropharmacology and neurotoxicity of 3,4-methylenedioxymethamphetamine. Gudelsky GA; Yamamoto BK Methods Mol Med; 2003; 79():55-73. PubMed ID: 12506690 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]